Drugs / Nabumetone
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | RELAFEN | — | 1991-12-24 | fda.gov ↗ |
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01638962 Comparator | Aug 2012 → Aug 2015 | osteoarthritis, knee | University of Southern Denmark | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2003-04-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Settlement of Litigation with GSK On Nabumetone tevapharm.com ↗ |
| 2002-08-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Comments on Court Affirmation of Relafen® Patent Challenge tevapharm.com ↗ |
| 2001-08-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Wins Nabumetone Lawsuit Will Commence Sales of Generic Equivalent of Relafen® Immediately tevapharm.com ↗ |
| 2000-06-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceutical Industries Ltd Receives Final FDA Approval of Nabumetone 750mg 180 Days Market Exclusivity Under Paragraph IV tevapharm.com ↗ |
| 2000-05-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceutical Industries Ltd Receives Final FDA Approval of Nabumetone 500 mg 180 Days Market Exclusivity Under Paragraph IV tevapharm.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nabumetone | “Nabumetone” NCT01638962 ↗ |
| Known as | BRL 14777 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1070 ↗ |
| Known as | Nabumetona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1070 ↗ |
| Known as | NSC-758623 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1070 ↗ |
| Known as | Relafen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1070 ↗ |
| Known as | Relifex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1070 ↗ |
| Action | Inhibit | “Cyclooxygenase-2 inhibitor” CHEMBL1070 ↗ |
| Modality | Small molecule | — CHEMBL1070 ↗ |
| Target | PTGS2 | “Cyclooxygenase-2 inhibitor” CHEMBL1070 ↗ |